$PFE Company News Here are the best-performing stocks

New Post Public Reply Private Reply Replies (0) Message Board

Jan 13, 2015 at 1:04 PM

$PFE Company News

Here are the best-performing stocks so far in 2015 11:47 a.m. Jan. 9, 2015 - Philip van Doorn
Drug trials, upgrades boost health-care sector 11:57 a.m. Jan. 8, 2015 - Russ Britt
Younger workers are driving employers to choose urban locations 10:54 a.m. Jan. 5, 2015 - Eliot Brown
Pfizer acquires Redvax for its potential herpes vaccine 8:17 a.m. Jan. 5, 2015 - Angela Chen
Run, don’t walk, away from this year’s top performer 8:29 a.m. Dec. 31, 2014 - Mark Hulbert
Are consumers getting gouged on health care? 9:35 a.m. Dec. 30, 2014 - Russ Britt
’Tis the season for buying stocks dumped for tax reasons 9:16 a.m. Dec. 24, 2014 - Michael Brush
Health-care sector taking a broad beating as pricing fears grow 2:39 p.m. Dec. 23, 2014 - Tomi Kilgore
What I learned with my 10 stock recommendations a year ago 6:00 a.m. Dec. 23, 2014 - Diana Furchtgott-Roth
How to find ‘winners’ among the worst S&P 500 stocks 5:22 p.m. Dec. 22, 2014 - Philip van Doorn
Stocking stuffers 12:27 p.m. Dec. 17, 2014 - Mark Hulbert
Boeing’s shares get lift from dividend hike, buyback 7:23 p.m. Dec. 15, 2014 - MarketWatch
U.S. stocks end choppy session lower 4:44 p.m. Dec. 15, 2014 - Barbara Kollmeyer
Pfizer, OPKO Health partner on growth-hormone treatment 1:50 p.m. Dec. 15, 2014 - Angela Chen
Opko Health's stock soars after Pfizer development agreement 8:15 a.m. Dec. 15, 2014 - Tomi Kilgore
Opko's stock jumps 8.8% premarket after Pfizer development agreement 8:07 a.m. Dec. 15, 2014 - Tomi Kilgore
Opko Health, Pfizer team up to develop Opko's GHD treatment 8:06 a.m. Dec. 15, 2014 - Tomi Kilgore
Drug makers face another $65 billion patent cliff 12:41 p.m. Dec. 10, 2014 - Russ Britt
Biogen's Alzheimer's surprise 11:24 a.m. Dec. 9, 2014 - The Trading Deck
Visa, Goldman Sachs powering Dow to 18,000 4:29 p.m. Dec. 5, 2014 - Tomi Kilgore

Dow Jones (DJIA) Today: Pfizer (PFE) Higher 12:00 p.m. Today - TheStreet.com
Bristol’s Lung Cancer Drug Aces Trial, Cheers Bulls 10:58 a.m. Today - Barrons.com
TiGenix: A Deeply Undervalued Stem Cells Company With Upcoming Catalysts 9:59 a.m. Today - Seeking Alpha
TiGenix: A Deeply Undervalued Stem Cell Company With Upcoming Catalysts 9:59 a.m. Today - Seeking Alpha
Deal Making In The Healthcare Industry 9:08 a.m. Today - Seeking Alpha
Medical Marijuana Goes to Market in Canada 3:10 a.m. Today - InvestorPlace.com
Argos Therapeutics Falls on Disappointing Phase IIb HIV Data - Analyst Blog 4:20 p.m. Jan. 12, 2015 - Zacks.com
Regeneron Can Generate 25% Upside for Investors 1:44 p.m. Jan. 12, 2015 - Barrons.com
3 Stocks Advancing The Drugs Industry 12:13 p.m. Jan. 12, 2015 - TheStreet.com
5 Biotech Stocks With Explosive Drug Pipelines 8:01 a.m. Jan. 12, 2015 - InvestorPlace.com
Dow 30 Stock Roundup: Pfizer Acquires Redvax, Microsoft Launches Affordable Internet-ready Phone - Analyst Blog 2:48 p.m. Jan. 9, 2015 - Zacks.com
3 Pharma Stocks That Soared Past Pfizer in 2014 - Analyst Blog 2:30 p.m. Jan. 9, 2015 - Zacks.com
The Bullish and Bearish Case for Pfizer in 2015 10:37 a.m. Jan. 9, 2015 - 247WallSt.com
Update: Pfizer's Palbociclib Is Closer To Approval Than Expected 8:23 p.m. Jan. 8, 2015 - Seeking Alpha
FDA clears Daiichi-Sankyo anticoagulant 7:55 p.m. Jan. 8, 2015 - Seeking Alpha
Pfizer, FDA Continue Talks on Breast-Cancer Drug 1:13 p.m. Jan. 8, 2015 - The Wall Street Journal Interactive Edition
Approval appears likely for Pfizer breast cancer candidate 12:48 p.m. Jan. 8, 2015 - Seeking Alpha
Income Ideas for 2015 11:03 a.m. Jan. 8, 2015 - Barrons.com
Dow Jones (DJIA) Today: Pfizer (PFE) Higher 11:00 a.m. Jan. 8, 2015 - TheStreet.com
5 Potential Blockbuster Drugs Set To Launch In 2015 7:02 a.m. Jan. 8, 2015 - Investors Business Daily

23andMe Announces Collaboration with Pfizer Inc. to Conduct Genetic Research Through 23andMe's Research Platform 9:00 a.m. Jan. 12, 2015 - PR Newswire - PRF
HemoShear Announces Collaboration with Pfizer Inc. To Help Identify and Predict Drug-Induced Vascular Injury for Early Stage Compounds 8:00 a.m. Jan. 12, 2015 - PR Newswire - PRF
Pfizer Provides Update on IBRANCE® (palbociclib) 8:31 a.m. Jan. 8, 2015 - BusinessWire - BZX
Repligen Receives Milestone Payment From Pfizer 7:30 a.m. Jan. 8, 2015 - GlobeNewswire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference 10:01 a.m. Jan. 6, 2015 - BusinessWire - BZX
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments 7:30 a.m. Jan. 6, 2015 - PR Newswire - PRF
Pfizer Acquires Redvax GmbH 7:30 a.m. Jan. 5, 2015 - BusinessWire - BZX
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
Factors Moving Markets: Complementary Research on GlaxoSmithKline, Cintas, Deere, Thermo Fisher and Pfizer 9:10 a.m. Dec. 19, 2014 - PR Newswire - PRF
Pan American Fertilizer (TSX.V: PFE, Frankfurt: 6GF) Provides an Update on its Operations and Audit Filings and Announces Transfer to NEX 12:48 p.m. Dec. 18, 2014 - ACCESSWIRE
Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia 8:00 a.m. Dec. 18, 2014 - BusinessWire - BZX
Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy 8:01 a.m. Dec. 17, 2014 - BusinessWire - BZX
Pfizer Invites Public to View and Listen to Webcast of January 27 Conference Call with Analysts 10:00 a.m. Dec. 16, 2014 - BusinessWire - BZX
Meningococcal Meningitis Survivor and TV Personality Amy Purdy and Pfizer Launch Take Action Against Meningitis 8:02 a.m. Dec. 16, 2014 - BusinessWire - BZX
Pfizer Announces Palbociclib PALOMA-1 Data Published in The Lancet Oncology 6:30 p.m. Dec. 15, 2014 - BusinessWire - BZX
Pfizer Declares First-Quarter 2015 Dividend 12:06 p.m. Dec. 15, 2014 - BusinessWire - BZX
InvestorsObserver releases comments on Pfizer, FedEx, Nike, General Mills, and DR Horton 9:31 a.m. Dec. 15, 2014 - PR Newswire - PRF
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines 9:10 a.m. Dec. 12, 2014 - PR Newswire - PRF
Actavis Launches Generic Version of Celebrex® 9:28 a.m. Dec. 10, 2014 - PR Newswire - PRF
Pfizer and Brenda Strong Encourage Women to Change the Conversation on Sexual Health Post-Menopause 9:02 a.m. Dec. 10, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swanson Nexus Pro Launch: Boost for Dietitians

By Lucas Young Updated Oct 24, 2026 Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Ping An's Bold Green Moves Ahead of APEC 2026

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...